Expert Content | Pfizer CentreOne

Your Questions Answered - Highly Potent Oral Solids Q&A

Pfizer CentreOne’s OSD experts answer your questions following our recent webinar on the challenges and considerations for a highly potent oral solids project.

The path to a secure supply chain – 10 questions to ask

In this e-Book, Jim Carr, Operations Lead for APIs & Intermediates at Pfizer CentreOne discusses the 10 key questions to ask when diversifying your API supply chain and how our team of experts can work with you to achieve this.

Highly Potent Oral Solids: Challenges and Considerations | Webinar

In this webinar Pfizer CentreOne’s oral solids (OSD) experts discuss key consideration highly potent oral solids (HPOSD), focusing on three key challenges faced during development and manufacture.

Why The Right Partner is Key to Successful Drug Innovation

At Pfizer CentreOne, we are proud to collaborate with pioneering companies in navigating the drug development journey to bring their innovations to market and transform the lives of patients read about how we make it happen.

Your Questions Answered - Technology Transfer in Sterile Injectables

Pfizer CentreOne’s sterile injectables experts answer your questions following our recent webinar on the three phases of a technology transfer on a sterile injectable project.

Starting your sterile injectables program off on the right foot

How can drug sponsors and developers leverage these increasingly strategic commercial fill/finish partnerships? Product development experts Jennifer Quint and Daniel Lenz at Pfizer CentreOne offer their tips on how drug sponsors and developers can put programs on a firmer footing.

Quality Attributes For Strategic Small Molecule API Partners

Tom Wilson, Contract Manufacturing Lead at Pfizer CentreOne, offers insights for picking small molecule development and manufacturing partners based on the following strategic quality attributes (SQAs):

Five Dangers of an Insecure API Supply Chain

In this e-book Ken Ball, Commercial Operations Lead for APIs & Intermediates at Pfizer CentreOne discusses five dangers of an insecure API supply chain.

Top Four Considerations for Tech Transfer Performance

Whether you are a drug developer searching for a CDMO partner for the first time, rising to a new role, or a veteran scrambling to fill a gap in your supply chain, there are four key considerations for gauging strong technology transfer performance: geographic footprint, technology, regulatory co

Culture of Confidentiality: Our Promise to Customers

When speaking to potential customers, we often encounter the misconception that partnering with an embedded CDMO like Pfizer CentreOne puts your intellectual property (IP) at risk. Yet this is not at all the case.

A Year in Review: 2020 API Supply Chain Trends and 2021 Predictions

It has been extremely gratifying for everyone here in Kalamazoo, Michigan to have been in pharma’s corner in 2020, helping the industry from behind the scenes, manufacturing and delivering supplies of critical treatments.

Looking ahead: Today’s technical trends shaping 2021 priorities

A range of new treatment and administration routes are being introduced to pharma’s pipeline, bringing new complexities and prompting demand for experienced CDMOs.

Header image of scientist for 2021 CDMO trends blog

Insights & Resources